
Sign up to save your podcasts
Or


How can sponsors spend upwards of $50m on phase 3 trials and still struggle to fill them? Jim McAleer, President and CEO of Alzheimer's Orange County, has an answer that has nothing to do with the protocol.
On this episode of Impactful Breakthroughs, he speaks with Laura Brencher, VP of Patient Advocacy at Leapcure, about why trusted community organizations are the practical route into clinical trials. Alzheimer's OC is an independent nonprofit providing care consultations, education, support groups and adult day health services to families living with dementia. Jim has run the organization for 22 years and has expanded their reach to now support over 30,000 people a year.
Jim and Laura cover drug developments which were “always 18 months away” without ever arriving, his hopes for the future of research in the space, and why it’s so critical for patients to be seen as early as possible. You’ll also hear about the many ways Jim and his team holistically support families by connecting them with art, culture, and faith.
The throughline throughout their conversation is that community organizations are the ones deservedly earning trust from the patients they serve. Treating them as the conduit to successful trials is the fastest honest route to enrollment.
Timestamps
00:00 Episode Start
01:55 How Jim got into the Alzheimer's space
03:10 What changed in the past 22 years
05:30 Dementia as the umbrella term
07:20 The caregiver experience up close
11:00 Inside Alzheimer's Orange County's programs
12:50 Why art, music and faith last longer
15:20 Connecting families to clinical research
17:45 What a good sponsor partnership looks like
20:10 Why families do or don't join trials
21:55 The hardest parts of running a nonprofit
25:30 Jim's career highlight and closing reflections
Key Takeaways
Guest Shoutouts
Resources
While clinical science has made tremendous strides over the last few decades, the clinical operations stringing it all together have barely moved. Today’s guest, Leesa Gentry, can’t believe that gap still exists, and has spent most of her career working on it.
Leesa is the Chief Clinical Officer at RenovoRX, a Bay Area based life sciences company developing innovative targeted oncology therapies and delivery systems. On this episode of Impactful Breakthroughs, she speaks with Zach Gobst about lean teams, sponsor and CRO relationships, and where AI belongs in clinical research.
A consistent throughline in their conversation is Leesa’s dedication to fostering human relationships to best advance the research. She believes that CRO dynamics are inherently set up to be adversarial with constant cost and time pressure. With most sponsors “rolling studies into a ball and tossing it over a fence,” her solution is to envelop CROs directly into her teams, empowering them to truly contribute.
Her take on AI is direct and actionable: It’s here to stay, so figure out how you can use it to clear your head so you can think about what is around the corner, and keep a human in anything that involves patient care.
Timestamps
00:00 Episode Start
02:30 How Leesa went from psychology to clinical research
05:00 Precision medicine and the end of the linear path
06:50 What led Leesa to RenovoRx over two other offers
08:05 A de-risked drug delivered straight to the tumor
11:15 What a lean clinical team actually needs
13:55 Why Leesa is often called a cowboy
20:25 Building one team across cultures
23:10 Running a Phase III without a CRO
30:45 Invest in metrics that actually matter
32:10 What 30 years of revolutions taught Leesa about AI
36:50 Leesa's mentors and closing reflections
Key Takeaways
Guest Shoutouts
Resources
What could clinical research learn from an industry where nothing ships until every system works perfectly in tandem with one another? Dave Hine, AVP of Financial Services at Suvoda, brings a deep background in rigorous systems engineering to today’s episode of Impactful Breakthroughs.
Suvoda is a global clinical trial technology company which provides a unified software platform to manage complex and time-sensitive clinical studies. In today’s conversation, Dave speaks with host Zach Gobst about what an aerospace engineer noticed when he walked into clinical research and could not stop noticing. Dave studied aerospace engineering, worked flight test and computational fluid dynamics software for the Navy, and joined Greenphire in 2018 as its only sales engineer. Today, he leads the team focused on site payments and budgeting.
The two of them get into interoperability and why it stalls in clinical trials, using military technology as the counterexample. Despite having parts manufactured by a handful of private agencies, each element of an F-18 is federally mandated to work seamlessly together. They also cover how COVID was the moment the public finally understood what a clinical trial was, and what survived from the decentralized trial wave.
The throughline is a habit most listeners can use directly: treat every process, vendor relationship, and team decision as one system, then ask who is accountable when a piece of it fails. That is the lens Dave brings to site payments, and it holds up as well in a study budget as it does on an aircraft.
Timestamps
00:00 Episode Start
01:40 Dave’s journey to aerospace engineering
02:55 Nine years of deep systems experience
04:10 What brought Dave to clinical trials in 2018
05:20 The importance of interoperability
08:45 Why Dave stayed in clinical trials
10:50 COVID as a turning point for the entire industry
12:50 Assume best intent, in both directions
16:40 Delegation, standards, and leading a team
23:30 Where AI helps and where it should not
26:20 Advice, mentors, and thank yous
Key Takeaways
Guest Shoutouts
Resources
After 30 years in clinical research, most people would tell you they've seen it all. But for today's guest, Dr. Karen Correa, three decades in the industry has only deepened her conviction that it’s less critical to know everything, and much more important to know everyone.
Karen is the VP of Clinical Development Operations at Boehringer Ingelheim, and on this episode of Impactful Breakthroughs she speaks with Zach Gobst about what it really takes to build teams and cultures that deliver for patients.
The two talk about why culture is the real unmet need in clinical development today. When processes, science, and timelines are all clearly established, company culture is the thing that can't be downloaded or rushed, and yet it's where everything begins and ends. Karen also opens up about the mentors who shaped her character, each pouring something different into her: truth, compassion, curiosity, and courage.
And when it comes to the inevitable challenges that come with a career of this scope, Karen has a reframe that stays with you. A delay is not a denial. Keep knocking. That no is going to become a yes someday. Because at the end of it all, she's never lost sight of why the work matters, and that's exactly the kind of north star that keeps the best leaders going.
Timestamps
00:00 Episode Start
01:45 How Karen's career in clinical research began
04:45 Understanding the patient experience from every angle
05:30 Why culture is the real unmet need in pharma
09:00 The mentors who shaped Karen's character and courage
12:30 Reframing challenges as learning opportunities
15:25 Finding your circle and embracing vulnerability
16:00 Being intentional about personal growth
17:15 How Karen is approaching AI today
19:55 What's energizing Karen about the future of clinical research
Key Takeaways
Guest Shoutouts
Resources
What does it look like to truly amplify the voices of those suffering from a rare disease, especially when you yourself have such a personal connection? On this episode of Impactful Breakthroughs, Zach Gobst sits down with Kate Stratton, Executive Director of Lipodystrophy United, a patient-driven global community dedicated to improving the lives of those affected by lipodystrophy through advocacy, community, and research.
Kate shares how her empathetic approach to patient advocacy was shaped. From her own mother’s experience navigating a 37-year diagnostic odyssey, to her experiences working with Planned Parenthood and asylum seekers, she emphasizes the importance of direct conversations rather than assumptions. You’ll also hear Kate’s journey navigating imposter syndrome and her advice for any young entrepreneurs out there looking to make their ideas a reality.
This conversation is a testament to what happens when personal experience, genuine empathy, and a refusal to wait for permission all come together in one person.
Timestamps
00:00 Episode Start
01:55 Kate's personal path into patient advocacy
04:15 Lipodystrophy and how it affects the body
07:00 The common thread across all advocacy work
09:25 Patient voices matter most
12:15 Ensuring no one gets put in the wrong box
14:45 Being a young leader and navigating imposter syndrome
16:20 What Kate has learned from openness and collaboration
19:15 What's next for Lipodistrophy Untied
21:45 Kate’s advice for younger generations
Key Takeaways
Guest Shoutouts
Resources
How far can curiosity take you when you’re not afraid of the unknown? For today’s guest, Francesca Barone, it led her across continents and disciplines as she navigated her way to the forefront of cancer immunotherapy. Francesca is the Chief Scientific Officer at Candel Therapeutics, and on this episode of Impactful Breakthroughs she speaks with Zach Gobst about how Candel is developing multimodal biological immunotherapies to help patients fight cancer.
Francesca shares the driving force, her “backpack theory,” behind the journey she’s taken. Rather than settling into comfort, she believes every few years you should pack up what you've learned and head toward a new challenge entirely. It’s a belief that has carried her from academic rheumatology to leading cutting-edge oncology drug development, navigating language barriers, cultural shifts, and an industry that wasn't yet ready to believe in what her team was building.
She also shares what it took to push Candel's novel intratumoral delivery approach through years of skepticism, why her physician background has been her greatest superpower in biotech, and what it really means to keep patients at the center even when your work may feel far removed. Behind every compassionate use request, every data point, and every clinical trial, there is a patient and a family. And for Francesca, that's always been reason enough to keep going.
Timestamps
00:00 Episode Start
01:45 Why Francesca moved from academia to biotech
03:55 The power of stretching beyond your comfort zone
09:30 You're only as good as your team
10:15 Candel's novel approach to fighting cancer
13:35 Overcoming skepticism and remaining committed
17:05 The human side of drug development
19:20 A patient stories that say it all
23:25 Mentors who shaped Francesca’s journey
29:30 Closing reflections on purpose and impact
Key Takeaways
Guest Shoutouts
Resources
What happens when a career built on the cutting edge of health technology suddenly extends to become deeply personal? On this episode of Impactful Breakthroughs, Zach Gobst is joined by longtime friend Becky Weber, the EVP of Sales at Lunit Cancer Screening. Lunit, formerly Volpara Health, provides AI-powered software for breast cancer screening and early detection, supporting over one million screenings annually.
With 20 years working at the intersection of health and technology, Becky walks through her journey from shadowing surgeries as a teenager, to helping build HealthKit at Apple, to ultimately joining the team at Lunit following her own breast cancer diagnosis. You’ll hear her share why mission alignment has proven to be the secret in Lunit’s successful merger with Volpara, what she believes it’ll take to navigate regulatory hurdles safely in the AI era, and how her perspective on life and career has completely pivoted.
Equal parts personal story and industry insight, this conversation serves as a reminder that the most powerful driver in health technology is the reason behind it.
Timestamps
00:00 Episode Start
01:35 Becky's journey in health tech
04:05 A breast cancer diagnosis which changed it all
08:45 Following your passions
12:09 Prioritizing team impact over personal politics
13:45 Why startups beat big companies for the puzzle-solvers
14:45 Lunit's two-sided platform and the AI difference
17:10 The interval cancer study proving their work
20:25 Hiring for personal connection to the mission
22:10 Mentors who made a difference
22:50 The convergence of research, product, and diagnosis
25:00 AI, regulation, and the rocket ship problem
Key Takeaways
Guest Shoutouts
Resources
When all of the experts around you say it’s impossible to move the needle forward, how do you still maintain commitment to your research and patients? On the very first episode of Impactful Breakthroughs, Zach Gobst is joined by Jennifer Good, the President & CEO of Trevi Therapeutics, to explore why she has dedicated the past fifteen years to tackling one of medicine’s most overlooked conditions: chronic cough.
Jennifer traces her path from running Pennwest Pharmaceuticals to negotiating a promising compound out of an acquisition and building Trevi from her kitchen table into the $2B public company it is today. She shares how a background in chronic pain research gave her and Co-Founder Dr. Thomas Sciascia a uniquely brain-centered lens on cough, and why listening closely to patients led them to double down on IPF when key opinion leaders told them to walk away. Equal parts science story and entrepreneurial journey, this conversation is a candid look at what perseverance, patient focus, and the willingness to evolve really look like in biotech.
Timestamps
00:00 Episode Start
03:00 Starting Trevi Therapeutics from the kitchen table
05:45 Advice for early entrepreneurs
07:30 Setting checkpoints and sticking to them
08:45 What was missing on chronic cough and IPF
12:45 How chronic pain research unlocked a new view of cough
18:45 Where Trevi fits into the patient experience
22:45 Reflections on her 15-year journey
25:30 Evolving the team as the company grows
32:00 Giving back through rare disease boards and community
34:45 Mentorship shoutouts
Key Takeaways
Guest Shoutouts
Resources
What does it take to protect the research that could one day save your sight? On this episode of Leap Together, Zach Gobst is joined by Dan Igniewski, Executive Director of the National Alliance for Eye and Vision Research (NAEVR) and the Alliance for Eye and Vision Research (AEVR). With over 20 years in government affairs and patient advocacy, Dan has become one of Washington's most persistent voices for vision research funding, and today's conversation shows exactly why that work matters.
Dan traces his path from early healthcare policy work to championing the National Eye Institute's independence on Capitol Hill, sharing how vision science is quietly leading some of medicine's most exciting frontiers, from the first FDA-approved gene therapy to AI-powered diagnostics and stem cell breakthroughs. He also unpacks NAEVR's “See What Matters” campaign, the mechanics of effective coalition building, and what it really takes to align patients, providers, researchers, and industry around a single message when federal funding is on the line.
Timestamps
00:00 Episode start
01:45 Dan's background and path to advocacy
03:55 What makes vision research unique
05:45 Parallels between policy and clinical research
06:55 Bipartisan support for NIH and the National Eye Institute
08:00 Career inflection points and advocacy wins
11:00 The See What Matters campaign
14:50 Shared challenges in patient engagement
16:55 What makes advocacy most effective
19:40 Mentorship and career guidance
23:15 The power of persistence and confidence
25:30 Closing thoughts
Key Takeaways
Resources
What happens when a neuroscientist follows his curiosity from the brain to the soil, and then to the stars? In this episode of Leap Together, Zach Gobst sits down with Dr. Joshua Ortiz-Guzman, a gene therapy engineer and developmental neuroscientist turned clinical research leader, industrial biotechnologist, and soil health innovator. Joshua's work spans an unusually wide range: building clinical research capacity in underserved El Paso, Texas; developing microbial biochar technologies that restore degraded soils; banking stem cells to rigorously track regenerative medicine outcomes; and orienting all of it toward a long-term vision of human longevity and space exploration.
This episode explores how environmental health and human health are deeply interconnected, and why that connection is chronically underappreciated in clinical research. Joshua shares how his PhD on brain-driven food intake led him down a rabbit hole from farm-to-table agriculture to emerging environmental contaminants like PFAS ("forever chemicals"), and why he believes the clinical research community can't fully understand drug outcomes without accounting for the environments patients live in.
He also reflects candidly on the challenges of building a research program from scratch in El Paso, a predominantly Spanish-speaking, medically underserved region where providers are overstretched, community trust requires intentional outreach, and groups like the Medical Center of the Americas are making real strides through “promotoras” led education. Joshua's journey from academic idealism to real-world business acumen, from soil pilots in Chihuahua and Colombia with Aurum Tech to a Florida-based stem cell bank called Prodigy Cells, is a rare example of evidence-first rigor applied consistently across human health and environmental systems.
From the publisher's feed